You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.

    SBC: PROMUTECH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Synactix Pharmaceuticals I-Corps Application

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory

    SBC: Botanisol LLC            Topic: R

    DESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 101

    DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Reduced gluten cereal grains

    SBC: Arcadia Biosciences, Inc.            Topic: 300

    DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Slip Flow Chromatography

    SBC: BIOVIDRIA, INC.            Topic: 100

    DESCRIPTION provided by applicant The goal of this STTR Phase II collaboration between Purdue University and bioVidria Inc is to commercialize disruptive new technology for protein chromatography and then maximize its impact by serving the fastest growing segment of the pharmaceutical industry protein drugs The product is a reversed phase chromatography column that uses silica particles of ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD, LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)

    SBC: IRON HORSE DIAGNOSTICS, INC.            Topic: 101

    DESCRIPTION provided by applicant Amyotrophic lateral sclerosis ALS or Lou Gehrigandapos s disease is a fatal neurodegenerative disease with a typical lifespan of years after diagnosis The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness muscle fasciculations or increasing difficulties in speech or breathing No definitive diagnost ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Reversal of Myocardial Infarction by Localized Stimulation

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government